<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781844</url>
  </required_header>
  <id_info>
    <org_study_id>SHP634-101</org_study_id>
    <secondary_id>2015-004757-40</secondary_id>
    <nct_id>NCT02781844</nct_id>
  </id_info>
  <brief_title>Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism</brief_title>
  <acronym>PARALLAX</acronym>
  <official_title>An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to characterize the effects of twice daily administration of
      rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and
      tolerability over the course of 24 hours as compared with the current once daily dosing
      regimen of marketed rhPTH(1-84) (marketed in the United States as NatparaÂ® and in the EU as
      Natpar).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">March 8, 2019</completion_date>
  <primary_completion_date type="Actual">March 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose ; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. Tmax of baseline adjusted rhPTH(1-84) was reported. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. Cmax of baseline adjusted rhPTH(1-84) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUClast of baseline adjsuted plasma rhPTH(1-84) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve Extrapolated to Infinity (AUCinf) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUCinf of baseline adjusted rhPTH(1-84) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to 24 Hours Post the First Dose (AUC0-24) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC0-24 of baseline adjusted rhPTH(1-84) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Curve From Time Zero to 12 Hours Post the First Dose (AUC0-12) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC0-12 of baseline adjusted rhPTH(1-84) was reported. AUC(0-12) was planned, analyzed and reported only in participants who received BID treatment ( Treatment A, Treatment C, Treatment D, Treatment F).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Curve From Time of the Second Dose to 12 Hours Post the Second Dose (AUC12-24) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>BID: 12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC12-24 of baseline adjusted rhPTH(1-84) was reported. AUC(12-24) was planned, analyzed and reported only in participants who received BID treatment ( Treatment A, Treatment C, Treatment D, Treatment F).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t1/2) of Baseline Adjusted rhPTH(1-84)</measure>
    <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
    <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. T1/2 of baseline adjusted rhPTH(1-84) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve That is Above the Baseline, From Time 0 to 24 Hours (AUCabove) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCabove of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 was reported. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve That is Below the Baseline, From Time 0 to 24 Hours (AUCbelow) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCbelow of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Effect (TEmax) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. TEmax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Effect (Emax) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. Emax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve That is Above the Baseline, From Time 0 to 24 Hours (AUCabove) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</measure>
    <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCabove of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve That is Below the Baseline, From Time 0 to 24 Hours (AUCbelow) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</measure>
    <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCbelow of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Effect (TEmax) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</measure>
    <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. TEmax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Effect (Emax) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</measure>
    <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
    <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. Emax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Urinary Calcium Excretion to Total Relative Amount of Creatinine Over 24 Hours by Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Total amount of urinary calcium excretion to total relative amount of creatinine over 24 hours by Day -1 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Urinary Calcium Excretion to Total Relative Amount of Creatinine Over 24 Hours by Day 1/ Day 2</measure>
    <time_frame>Day 1- QD: Pre-dose up to 24 hours post dose, Day 2- BID: Pre-dose up to 24 hours post dose</time_frame>
    <description>Total amount of urinary calcium excretion to total relative amount of creatinine over 24 hours by Day 1/ Day 2 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Urinary Excretion of Calcium Over 24 Hours by Day -1</measure>
    <time_frame>Day -1</time_frame>
    <description>Total urinary excretion of calcium over 24 Hours by Day -1 was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Urinary Excretion of Calcium Over 24 Hours by Day 1/ Day 2</measure>
    <time_frame>Day 1- QD: Pre-dose up to 24 hours post dose, Day 2- BID: Pre-dose up to 24 hours post dose</time_frame>
    <description>Total urinary excretion of calcium over 24 hours by Day1/Day 2 was reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAE's)</measure>
    <time_frame>From signing of informed consent up to follow up (up to Day 182)</time_frame>
    <description>An AE that occured during the study was considered a TEAE if it had a start date/time on or after the first dose of investigational product or if it had a start date before the date of the first dose of investigational product, but increased in severity on or after the date/time of the first dose of investigational product. Number of participants with TEAE's were reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hypoparathyroidism</condition>
  <arm_group>
    <arm_group_label>A/B or B/A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C/B or B/C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D/E or E/D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F/E or E/F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mcg rhPTH(1-84)</intervention_name>
    <description>Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.</description>
    <arm_group_label>A/B or B/A</arm_group_label>
    <arm_group_label>D/E or E/D</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50mcg rhPTH(1-84)</intervention_name>
    <description>Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4</description>
    <arm_group_label>C/B or B/C</arm_group_label>
    <arm_group_label>F/E or E/F</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100mcg rhPTH(1-84)</intervention_name>
    <description>Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.</description>
    <arm_group_label>A/B or B/A</arm_group_label>
    <arm_group_label>C/B or B/C</arm_group_label>
    <arm_group_label>D/E or E/D</arm_group_label>
    <arm_group_label>F/E or E/F</arm_group_label>
    <other_name>PTH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. An understanding, ability, and willingness to fully comply with study procedures and
             restrictions.

          2. Ability to voluntarily provide written, signed, and dated informed consent as
             applicable to participate in the study.

          3. Adult men or women aged greater than or equal (&gt;=) 18 years at the time of consent.
             The date of participant signature of the informed consent is defined as the beginning
             of the Screening Period. The Screening Period for this study may encompass both the
             Administrative Screening Period (if needed) and the Clinical Screening Period. For
             purposes of this inclusion criterion, age will only be assessed at the time the
             informed consent is first signed by the study participant.

          4. History of hypoparathyroidism for &gt;=12 months, post-diagnosis, inclusive of historical
             biochemical evidence of hypocalcemia with concomitant serum intact parathyroid hormone
             (PTH) concentrations below the lower limit of the laboratory normal range.

          5. Requirement for supplemental oral calcium treatment &gt;=1000 milligrams (mg) elemental
             calcium per day.

          6. Requirement for therapy with active forms of vitamin D at a minimum dose of &gt;=0.25
             microgram (mcg) per day (that is, &gt;=0.25 mcg calcitriol or equivalent per day).

          7. Serum calcium level within the laboratory normal reference range based on clinical
             chemistry lab results at the Clinical Screening Visit (based on central and/or local
             lab results) and Treatment Period 1, Day -2 (based on central and/or local lab
             results), or if outside of normal range, considered not clinically significant by the
             investigator.

          8. Urinary calcium excretion &gt;=200mg (5 millimolar [mmol])/24 hour (h), based on a
             24-hour collection, collected anytime during the Clinical Screening Period, but prior
             to check-in to the Clinical Research Center (CRC) at Treatment Period 1, Day -2 (based
             on central and/or local lab results).

          9. Serum magnesium level within the laboratory normal range at the Clinical Screening
             Visit or, if outside of normal range, considered not clinically significant by the
             investigator.

         10. Serum thyroid function tests within normal laboratory limits at the Clinical Screening
             Visit, or, if outside of normal range, considered as not clinically significant by the
             investigator.

         11. Serum 25-hydroxyvitamin D (25(OH)D) level between the lower limit of normal and
             1.5-fold the laboratory upper limit of normal, or, if outside of this range,
             considered not clinically significant by the investigator, at the Clinical Screening
             Visit.

         12. Serum creatinine less than (&lt;) 1.5 mg/ decilitre (dL) (&lt;133 micromole [mmol]/ litre
             [L]) AND estimated creatinine clearance greater than (&gt;) 60 millilitre (mL)/minute
             (&gt;1.002mL/ Second [s]) at the Clinical Screening Visit, and serum creatinine &lt;1.5
             mg/dL (&lt;133mmol/L) at Treatment Period 1, Day -2.

         13. Male or non-pregnant, non-lactating female who agrees to comply with any applicable
             contraceptive requirements of the protocol or females of non-childbearing potential.

        Exclusion Criteria:

          1. Participation in any other investigational drug study in which the last dose of
             investigational drug occurred within 3 months prior to Day 1 of Treatment Period 1 (or
             within 5 half-lives, if elimination half-life is greater than 18 days).

          2. Presence or history of a clinically significant disorder involving the cardiovascular,
             respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine (with
             exception of the condition under study), or neurologic system(s) or psychiatric
             disease as determined by the investigator.

          3. Known history of hypoparathyroidism resulting from an activation mutation in the
             calcium sensing receptor (CaSR) gene or impaired responsiveness to PTH
             (pseudohypoparathyroidism).

          4. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis
             other than hypoparathyroidism, including but not limited to, active hyperthyroidism;
             poorly controlled insulin-dependent diabetes mellitus or type 2 diabetes mellitus;
             severe and chronic cardiac, liver or renal disease; Cushing's syndrome; neuromuscular
             disease such as rheumatoid arthritis; myeloma; pancreatitis; malnutrition; rickets;
             recent prolonged immobility; active malignancy, bone metastases or a history of
             skeletal malignancies; primary or secondary hyperparathyroidism; a history of
             parathyroid carcinoma; hypopituitarism, acromegaly; or multiple endocrine neoplasia
             types 1 and 2, as determined by the investigator.

        5 . In male and female rats, parathyroid hormone caused an increase in the incidence of
        osteosarcoma (a malignant bone tumor). The occurrence of osteosarcoma was dependent on
        parathyroid hormone dose and treatment duration. This effect was observed at parathyroid
        hormone exposure levels ranging from 3 to 71 times the exposure levels in humans receiving
        a 100 mcg dose of rhPTH(1-84). Therefore, participant who are at increased baseline risk
        for osteosarcoma such as participant with Paget's disease of bone or unexplained elevations
        of alkaline phosphatase, pediatric and young adult participants with open epiphyses,
        participants with hereditary disorders predisposing to osteosarcoma or participant with a
        prior history of external beam or implant radiation therapy involving the skeleton are
        excluded.

        6. Participants who have a known history of hypercalcemia during initiation of treatment
        with PTH, PTH analogues or fragments of PTH.

        7. Participants who have a known history of hypocalcemia following abrupt withdrawal of
        treatment with PTH, PTH analogues or fragments of PTH.

        8. Participant dependent on regular parenteral calcium infusions (example, calcium
        gluconate) to maintain calcium homeostasis within 3 months prior to enrollment, as
        determined by the investigator.

        9. Use of the following medications prior to administration of investigational product
        within: 14 days- thiazide diuretics; 30 days - loop diuretics, lithium, systemic
        corticosteroids (medical judgment is required by the investigator. Primarily high doses of
        systemic corticosteroids [example, prednisone] should be excluded. Stable doses of
        hydrocortisone [example, as treatment for Addison's disease] may be acceptable); 3 months -
        calcitonin, cinacalcet hydrochloride, treatment with rhPTH(1-84) or N-terminal PTH or
        PTH-related peptide fragments or analogs; For females: changes in hormone replacement
        therapy within 3 months are excluded. Stable (&gt;=3 months) hormone replacement therapy is
        acceptable; 6 months - fluoride tablets, oral bisphosphonates, methotrexate, growth
        hormone, digoxin, raloxifene or similar selective estrogen receptor modulators (SERMs); 12
        months - intravenous bisphosphonates, drug or alcohol abuse, as determined by the
        investigator.

        10. Presence of any clinically significant results from laboratory tests, vital signs
        assessments, or electrocardiograms (ECGs), as judged by the investigator.

        11. Twelve-lead ECG values (average of triplicate readings) demonstrating QTc&gt;450
        millisecond (msec) (males) or &gt;470 msec (females) at the Clinical Screening Visit and/or
        any time points up to and including predose of Day 1 (Period 1).

        12. Any medical condition or prior therapy that, in the opinion of the investigator, would
        make the participant unsuitable for this study.

        13. Positive test result for any of the following viral infections at the Clinical
        Screening Visit: Hepatitis B surface antigen; hepatitis C; human immunodeficiency virus
        (HIV) 14. Known significant bleeding diathesis that could preclude multiple venipunctures
        as determined by the investigator.

        15. Participants who have donated a total of 100 mL to 499 mL of whole blood within 30 days
        prior to dosing, or participants who have donated a total of more than 499 mL of whole
        blood within 56 days prior to dosing.

        16. A positive screen for drugs of abuse at the Clinical Screening Visit, and/or a positive
        screen for drugs of abuse and alcohol at check-in to the CRC at Treatment Period 1.
        Participants taking prescription medications that might be detected during the urine screen
        for drugs of abuse may be enrolled per the investigator's medical judgment.

        17. History of a clinically significant illness during the 4 weeks prior to dosing (as
        determined by the investigator).

        18. History of any clinically significant surgery or procedure within the past 8 weeks, as
        determined by the investigator.

        19. History of an allergic response(s) to PTH or PTH analogs, or other clinically
        significant allergies, as determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Kentucky School of Medicine</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crescent City Clinical Research Center, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research (NOCCR) - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus N</city>
        <state>Central Jutland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <state>CsongrÃ¡d</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PÃ©csi TudomÃ¡nyegyetem</name>
      <address>
        <city>PÃ©cs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <results_first_submitted>March 6, 2020</results_first_submitted>
  <results_first_submitted_qc>March 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2020</results_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoparathyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02781844/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02781844/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in North America and Europe between 04 March 2017 (first participant first visit) to 08 March 2019 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 34 participants were enrolled and 33 completed the study. The study consisted of two treatment periods (Treatment period I and II) with four cohorts. Cohort I included Sequence AB and BA. Cohort II included Sequence CB and BC. Cohort III included Sequence DE and ED, Cohort IV included Sequence FE and EF.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort I: Treatment A / B</title>
          <description>Participants received 25 microgram (mcg) rhPTH(1-84) twice daily (BID) with no calcium for treatment period 1 and 100 mcg rhPTH(1-84) once daily (QD) with no calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of greater than or equal to (&gt;=) 5 days but less than or equal to (&lt;=) 30 days between the administration of 25 mcg BID and 100 mcg QD rhPTH(1-84).</description>
        </group>
        <group group_id="P2">
          <title>Cohort I: Treatment B / A</title>
          <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium for treatment period 1 and 25 mcg rhPTH(1-84) BID with no calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 100 mcg QD and 25 mcg BID rhPTH(1-84).</description>
        </group>
        <group group_id="P3">
          <title>Cohort II: Treatment C / B</title>
          <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with no calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 50 mcg BID and 100 mcg QD rhPTH(1-84).</description>
        </group>
        <group group_id="P4">
          <title>Cohort II: Treatment B / C</title>
          <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium for treatment period 1 and 50 mcg rhPTH(1-84) BID with no calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 100 mcg QD and 50 mcg BID rhPTH(1-84).</description>
        </group>
        <group group_id="P5">
          <title>Cohort III: Treatment D / E</title>
          <description>Participants received 25 mcg rhPTH(1-84) BID with calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 25 mcg BID and 100 mcg QD rhPTH(1-84).</description>
        </group>
        <group group_id="P6">
          <title>Cohort III: Treatment E / D</title>
          <description>Participants received 100 mcg rhPTH(1-84) QD with calcium for treatment period 1 and 25 mcg rhPTH(1-84) BID with calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 100 mcg QD and 25 mcg BID rhPTH(1-84).</description>
        </group>
        <group group_id="P7">
          <title>Cohort IV: Treatment F / E</title>
          <description>Participants received 50 mcg rhPTH(1-84) BID with calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 50 mcg BID and 100 mcg QD rhPTH(1-84).</description>
        </group>
        <group group_id="P8">
          <title>Cohort IV: Treatment E / F</title>
          <description>Participants received 100 mcg rhPTH(1-84) QD with calcium for treatment period 1 and 50 mcg rhPTH(1-84) BID with calcium for treatment period 2 in the morning on Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of 100 mcg QD and 50 mcg BID rhPTH(1-84).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included enrolled participants who had received at least 1 dose of rhPTH(1-84).</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort I: Treatment A/B or Treatment B/A</title>
          <description>Participants received either 25 mcg rhPTH(1-84) BID with no calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with no calcium for treatment period 2; or 100 mcg rhPTH(1-84) QD with no calcium for treatment period 1 and 25 mcg rhPTH(1-84) BID with no calcium for treatment period 2 in the morning of Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of rhPTH(1-84) or the first administration of rhPTH(1-84) in each period for QD or BID dosing, respectively.</description>
        </group>
        <group group_id="B2">
          <title>Cohort II: Treatment C/B or Treatment B/C</title>
          <description>Participants received either 50 mcg rhPTH(1-84) BID with no calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with no calcium for treatment period 2; or 100 mcg rhPTH(1-84) QD with no calcium for treatment period 1 and 50 mcg rhPTH(1-84) BID with no calcium for treatment period 2 in the morning of Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of rhPTH(1-84) or the first administration of rhPTH(1-84) in each period for QD or BID dosing, respectively.</description>
        </group>
        <group group_id="B3">
          <title>Cohort III: Treatment D/E or Treatment E/D</title>
          <description>Participants received either 25 mcg rhPTH(1-84) BID with calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with calcium for treatment period 2; or 100 mcg rhPTH(1-84) QD with calcium for treatment period 1 and 25 mcg rhPTH(1-84) BID with calcium for treatment period 2 in the morning of Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of rhPTH(1-84) or the first administration of rhPTH(1-84) in each period for QD or BID dosing, respectively.</description>
        </group>
        <group group_id="B4">
          <title>Cohort IV: Treatment F/E or Treatment E/F</title>
          <description>Participants receive either 50 mcg rhPTH(1-84) BID with calcium for treatment period 1 and 100 mcg rhPTH(1-84) QD with calcium for treatment period 2; or 100 mcg rhPTH(1-84) QD with calcium for treatment period 1 and 50 mcg rhPTH(1-84) BID with calcium for treatment period 2 in the morning of Day 1 of respective treatment periods. The 2 treatment periods were separated by a washout period of &gt; or = 5 days but &lt; or = 30 days between the administration of rhPTH(1-84) or the first administration of rhPTH(1-84) in each period for QD or BID dosing, respectively.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="9.06"/>
                    <measurement group_id="B2" value="48.9" spread="13.48"/>
                    <measurement group_id="B3" value="52.4" spread="13.31"/>
                    <measurement group_id="B4" value="45.8" spread="9.02"/>
                    <measurement group_id="B5" value="47.4" spread="11.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. Tmax of baseline adjusted rhPTH(1-84) was reported. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</description>
        <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose ; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
        <population>Pharmacokinetic (PK) analysis set consisted of all enrolled participants who did not have major protocol violations that affected the validity of the PK results, received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable postdose PK concentration value available for 1 dose regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Concentration (Cmax) During a Dosing Interval (Tmax) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. Tmax of baseline adjusted rhPTH(1-84) was reported. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</description>
          <population>Pharmacokinetic (PK) analysis set consisted of all enrolled participants who did not have major protocol violations that affected the validity of the PK results, received at least 1 dose of rhPTH(1-84) and had at least 1 evaluable postdose PK concentration value available for 1 dose regimen.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.108" lower_limit="0.18" upper_limit="14.07"/>
                    <measurement group_id="O2" value="7.083" lower_limit="0.17" upper_limit="13.50"/>
                    <measurement group_id="O3" value="0.333" lower_limit="0.17" upper_limit="4.17"/>
                    <measurement group_id="O4" value="1.000" lower_limit="0.15" upper_limit="14.00"/>
                    <measurement group_id="O5" value="12.167" lower_limit="0.17" upper_limit="13.50"/>
                    <measurement group_id="O6" value="0.667" lower_limit="0.12" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. Cmax of baseline adjusted rhPTH(1-84) was reported.</description>
        <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. Cmax of baseline adjusted rhPTH(1-84) was reported.</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.9" spread="50.9"/>
                    <measurement group_id="O2" value="213.6" spread="51.6"/>
                    <measurement group_id="O3" value="339.1" spread="137.8"/>
                    <measurement group_id="O4" value="120.9" spread="83.6"/>
                    <measurement group_id="O5" value="100.5" spread="106.2"/>
                    <measurement group_id="O6" value="240.8" spread="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUClast of baseline adjsuted plasma rhPTH(1-84) was reported.</description>
        <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure and at specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUClast of baseline adjsuted plasma rhPTH(1-84) was reported.</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure and at specific category.</population>
          <units>hour*picogram per milliliter (h*pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496.0" spread="34.1"/>
                    <measurement group_id="O2" value="653.2" spread="25.5"/>
                    <measurement group_id="O3" value="901.1" spread="448.5"/>
                    <measurement group_id="O4" value="205.0" spread="106.6"/>
                    <measurement group_id="O5" value="261.1" spread="77.6"/>
                    <measurement group_id="O6" value="1044.9" spread="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve Extrapolated to Infinity (AUCinf) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUCinf of baseline adjusted rhPTH(1-84) was reported.</description>
        <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure and at specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve Extrapolated to Infinity (AUCinf) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUCinf of baseline adjusted rhPTH(1-84) was reported.</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure and at specific category.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484.8" spread="48.4"/>
                    <measurement group_id="O2" value="677.7" spread="22.9"/>
                    <measurement group_id="O3" value="1567.6" spread="36.7"/>
                    <measurement group_id="O4" value="255.0" spread="198.3"/>
                    <measurement group_id="O5" value="600.8" spread="NA">Geometric CV% cannot be calculated for one single participant. This outcome measure was analyzed only in one participants for cohort IV.</measurement>
                    <measurement group_id="O6" value="1043.5" spread="50.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Curve From Time Zero to 24 Hours Post the First Dose (AUC0-24) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC0-24 of baseline adjusted rhPTH(1-84) was reported.</description>
        <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to 24 Hours Post the First Dose (AUC0-24) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC0-24 of baseline adjusted rhPTH(1-84) was reported.</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="944.6" spread="29.9"/>
                    <measurement group_id="O2" value="1357.6" spread="31.3"/>
                    <measurement group_id="O3" value="973.7" spread="334.6"/>
                    <measurement group_id="O4" value="577.6" spread="94.3"/>
                    <measurement group_id="O5" value="606.3" spread="135.3"/>
                    <measurement group_id="O6" value="1106.8" spread="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Curve From Time Zero to 12 Hours Post the First Dose (AUC0-12) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC0-12 of baseline adjusted rhPTH(1-84) was reported. AUC(0-12) was planned, analyzed and reported only in participants who received BID treatment ( Treatment A, Treatment C, Treatment D, Treatment F).</description>
        <time_frame>BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O4">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time Zero to 12 Hours Post the First Dose (AUC0-12) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC0-12 of baseline adjusted rhPTH(1-84) was reported. AUC(0-12) was planned, analyzed and reported only in participants who received BID treatment ( Treatment A, Treatment C, Treatment D, Treatment F).</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462.1" spread="29.9"/>
                    <measurement group_id="O2" value="665.2" spread="42.3"/>
                    <measurement group_id="O3" value="298.8" spread="113.9"/>
                    <measurement group_id="O4" value="220.2" spread="354.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Curve From Time of the Second Dose to 12 Hours Post the Second Dose (AUC12-24) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC12-24 of baseline adjusted rhPTH(1-84) was reported. AUC(12-24) was planned, analyzed and reported only in participants who received BID treatment ( Treatment A, Treatment C, Treatment D, Treatment F).</description>
        <time_frame>BID: 12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O4">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Curve From Time of the Second Dose to 12 Hours Post the Second Dose (AUC12-24) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. AUC12-24 of baseline adjusted rhPTH(1-84) was reported. AUC(12-24) was planned, analyzed and reported only in participants who received BID treatment ( Treatment A, Treatment C, Treatment D, Treatment F).</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479.0" spread="33.3"/>
                    <measurement group_id="O2" value="679.5" spread="25.5"/>
                    <measurement group_id="O3" value="245.2" spread="93.5"/>
                    <measurement group_id="O4" value="323.2" spread="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Half-Life (t1/2) of Baseline Adjusted rhPTH(1-84)</title>
        <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. T1/2 of baseline adjusted rhPTH(1-84) was reported.</description>
        <time_frame>QD: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12,16 and 24 hours post-dose; BID: Pre-dose,10,20,30 minutes,1,1.5,2,4,8,12 hours,12 hour 10 minutes,12 hour 20 minutes,12 hour 30 minutes,13 hours, 13 hour 30 minutes,14,16,20,22,24,28 and 36 hours post-dose</time_frame>
        <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure and at specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-Life (t1/2) of Baseline Adjusted rhPTH(1-84)</title>
          <description>Baseline-adjusted rhPTH(1-84) concentrations (participant- and period-specific) were calculated by subtracting baseline endogenous PTH from the raw PTH concentrations. The baseline was defined as premorning-dose endogenous rhPTH(1-84) level on Day 1 for each treatment period. T1/2 of baseline adjusted rhPTH(1-84) was reported.</description>
          <population>PK analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure and at specific category.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.739" spread="39.461"/>
                    <measurement group_id="O2" value="2.073" spread="38.704"/>
                    <measurement group_id="O3" value="1.973" spread="42.421"/>
                    <measurement group_id="O4" value="1.446" spread="62.293"/>
                    <measurement group_id="O5" value="1.773" spread="NA">Geometric CV% cannot be calculated for one single participant. This outcome measure was analyzed only in one participant for cohort IV.</measurement>
                    <measurement group_id="O6" value="2.190" spread="38.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve That is Above the Baseline, From Time 0 to 24 Hours (AUCabove) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCabove of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 was reported. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</description>
        <time_frame>Day -1</time_frame>
        <population>Pharmacodynamic (PD) analysis set consisted of all enrolled participants who did not have major protocol violations that affected the validity of the PD results, received at least 1 dose of rhPTH(1 84) and had at least 1 evaluable post-dose PD value available for 1 dose regimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve That is Above the Baseline, From Time 0 to 24 Hours (AUCabove) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCabove of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 was reported. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</description>
          <population>Pharmacodynamic (PD) analysis set consisted of all enrolled participants who did not have major protocol violations that affected the validity of the PD results, received at least 1 dose of rhPTH(1 84) and had at least 1 evaluable post-dose PD value available for 1 dose regimen.</population>
          <units>hour*millimoles per Liter (h*mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (Albumin-Corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.714" spread="1.5038"/>
                    <measurement group_id="O2" value="1.189" spread="1.5482"/>
                    <measurement group_id="O3" value="0.701" spread="0.9478"/>
                    <measurement group_id="O4" value="0.802" spread="0.7234"/>
                    <measurement group_id="O5" value="1.470" spread="1.7843"/>
                    <measurement group_id="O6" value="0.791" spread="0.8162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.672" spread="1.8280"/>
                    <measurement group_id="O2" value="1.190" spread="1.3884"/>
                    <measurement group_id="O3" value="0.616" spread="0.8793"/>
                    <measurement group_id="O4" value="0.934" spread="0.7920"/>
                    <measurement group_id="O5" value="1.890" spread="1.7930"/>
                    <measurement group_id="O6" value="1.162" spread="1.2725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve That is Below the Baseline, From Time 0 to 24 Hours (AUCbelow) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCbelow of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 was reported.</description>
        <time_frame>Day -1</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve That is Below the Baseline, From Time 0 to 24 Hours (AUCbelow) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCbelow of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 was reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (Albumin-Corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.283" spread="0.5173"/>
                    <measurement group_id="O2" value="0.380" spread="0.3621"/>
                    <measurement group_id="O3" value="1.291" spread="1.8883"/>
                    <measurement group_id="O4" value="0.637" spread="1.0314"/>
                    <measurement group_id="O5" value="0.434" spread="0.6786"/>
                    <measurement group_id="O6" value="0.816" spread="0.9874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" spread="0.4379"/>
                    <measurement group_id="O2" value="0.394" spread="0.3259"/>
                    <measurement group_id="O3" value="1.570" spread="1.9043"/>
                    <measurement group_id="O4" value="0.639" spread="0.9601"/>
                    <measurement group_id="O5" value="0.515" spread="0.6182"/>
                    <measurement group_id="O6" value="0.998" spread="1.3267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Effect (TEmax) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. TEmax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 were reported.</description>
        <time_frame>Day -1</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect (TEmax) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. TEmax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 were reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (Albumin-Corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="4.00" upper_limit="16.52"/>
                    <measurement group_id="O2" value="13.583" lower_limit="8.05" upper_limit="16.00"/>
                    <measurement group_id="O3" value="6.000" lower_limit="0.00" upper_limit="13.80"/>
                    <measurement group_id="O4" value="7.317" lower_limit="3.97" upper_limit="23.92"/>
                    <measurement group_id="O5" value="9.250" lower_limit="1.67" upper_limit="24.07"/>
                    <measurement group_id="O6" value="13.692" lower_limit="0.00" upper_limit="24.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="4.00" upper_limit="16.52"/>
                    <measurement group_id="O2" value="12.100" lower_limit="0.00" upper_limit="25.47"/>
                    <measurement group_id="O3" value="4.200" lower_limit="0.00" upper_limit="16.25"/>
                    <measurement group_id="O4" value="5.208" lower_limit="1.67" upper_limit="23.92"/>
                    <measurement group_id="O5" value="5.367" lower_limit="1.67" upper_limit="24.07"/>
                    <measurement group_id="O6" value="13.692" lower_limit="0.00" upper_limit="24.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Effect (Emax) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. Emax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 were reported.</description>
        <time_frame>Day -1</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect (Emax) of Baseline-Adjusted Serum Calcium Concentrations on Day -1</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. Emax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day -1 were reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>millimoles/Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (Albumin-Corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.284" spread="0.1495"/>
                    <measurement group_id="O2" value="0.110" spread="0.1098"/>
                    <measurement group_id="O3" value="0.102" spread="0.0892"/>
                    <measurement group_id="O4" value="0.098" spread="0.0539"/>
                    <measurement group_id="O5" value="0.148" spread="0.1398"/>
                    <measurement group_id="O6" value="0.107" spread="0.0783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.273" spread="0.1874"/>
                    <measurement group_id="O2" value="0.116" spread="0.1066"/>
                    <measurement group_id="O3" value="0.100" spread="0.0921"/>
                    <measurement group_id="O4" value="0.121" spread="0.0690"/>
                    <measurement group_id="O5" value="0.197" spread="0.1465"/>
                    <measurement group_id="O6" value="0.127" spread="0.0947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve That is Above the Baseline, From Time 0 to 24 Hours (AUCabove) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCabove of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
        <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve That is Above the Baseline, From Time 0 to 24 Hours (AUCabove) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCabove of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (albumin-corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.222" spread="1.2757"/>
                    <measurement group_id="O2" value="1.084" spread="0.8887"/>
                    <measurement group_id="O3" value="1.645" spread="1.1038"/>
                    <measurement group_id="O4" value="2.860" spread="4.1108"/>
                    <measurement group_id="O5" value="1.468" spread="1.5533"/>
                    <measurement group_id="O6" value="2.610" spread="1.5520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.060" spread="1.0398"/>
                    <measurement group_id="O2" value="0.715" spread="0.5001"/>
                    <measurement group_id="O3" value="1.769" spread="1.3569"/>
                    <measurement group_id="O4" value="3.259" spread="4.6635"/>
                    <measurement group_id="O5" value="1.540" spread="1.6227"/>
                    <measurement group_id="O6" value="2.456" spread="1.4576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve That is Below the Baseline, From Time 0 to 24 Hours (AUCbelow) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCbelow of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 was reported.</description>
        <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve That is Below the Baseline, From Time 0 to 24 Hours (AUCbelow) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. AUCbelow of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 was reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>h*mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (Albumin-Corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.085" spread="1.1804"/>
                    <measurement group_id="O2" value="0.393" spread="0.6320"/>
                    <measurement group_id="O3" value="0.197" spread="0.2940"/>
                    <measurement group_id="O4" value="0.309" spread="0.5883"/>
                    <measurement group_id="O5" value="0.548" spread="0.6416"/>
                    <measurement group_id="O6" value="0.316" spread="0.5706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.944" spread="1.1352"/>
                    <measurement group_id="O2" value="0.362" spread="0.3115"/>
                    <measurement group_id="O3" value="0.320" spread="0.5456"/>
                    <measurement group_id="O4" value="0.273" spread="0.4174"/>
                    <measurement group_id="O5" value="0.601" spread="0.6863"/>
                    <measurement group_id="O6" value="0.437" spread="0.7870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Effect (TEmax) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. TEmax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
        <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect (TEmax) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. TEmax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (albumin-corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.667" lower_limit="0.00" upper_limit="24.13"/>
                    <measurement group_id="O2" value="18.000" lower_limit="4.00" upper_limit="22.00"/>
                    <measurement group_id="O3" value="8.017" lower_limit="1.50" upper_limit="24.02"/>
                    <measurement group_id="O4" value="18.000" lower_limit="8.00" upper_limit="36.00"/>
                    <measurement group_id="O5" value="17.000" lower_limit="8.10" upper_limit="20.00"/>
                    <measurement group_id="O6" value="9.075" lower_limit="0.00" upper_limit="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.108" lower_limit="0.00" upper_limit="28.02"/>
                    <measurement group_id="O2" value="10.000" lower_limit="1.50" upper_limit="22.00"/>
                    <measurement group_id="O3" value="9.917" lower_limit="1.50" upper_limit="24.18"/>
                    <measurement group_id="O4" value="13.508" lower_limit="8.00" upper_limit="20.00"/>
                    <measurement group_id="O5" value="16.000" lower_limit="8.10" upper_limit="36.02"/>
                    <measurement group_id="O6" value="8.092" lower_limit="0.00" upper_limit="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Effect (Emax) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
        <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. Emax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
        <time_frame>Day1- QD: Pre-dose up to 24 hours post dose, Day2- BID: Pre-dose up to 36 hours post dose</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect (Emax) of Baseline-Adjusted Serum Calcium Concentrations on Day 1/Day 2</title>
          <description>Baseline-adjusted concentrations calculated by subtracting the appropriate baseline values from the raw concentrations at each time point. Emax of baseline-adjusted serum calcium (albumin-corrected) and total calcium (calcium [uncorrected]) concentrations on Day 1/Day 2 were reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium (albumin-corrected)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.146" spread="0.1031"/>
                    <measurement group_id="O2" value="0.120" spread="0.0746"/>
                    <measurement group_id="O3" value="0.173" spread="0.0825"/>
                    <measurement group_id="O4" value="0.205" spread="0.1999"/>
                    <measurement group_id="O5" value="0.160" spread="0.0994"/>
                    <measurement group_id="O6" value="0.216" spread="0.1252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.139" spread="0.1029"/>
                    <measurement group_id="O2" value="0.103" spread="0.0489"/>
                    <measurement group_id="O3" value="0.183" spread="0.0993"/>
                    <measurement group_id="O4" value="0.243" spread="0.2247"/>
                    <measurement group_id="O5" value="0.183" spread="0.0873"/>
                    <measurement group_id="O6" value="0.207" spread="0.1025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Urinary Calcium Excretion to Total Relative Amount of Creatinine Over 24 Hours by Day -1</title>
        <description>Total amount of urinary calcium excretion to total relative amount of creatinine over 24 hours by Day -1 was reported.</description>
        <time_frame>Day -1</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Urinary Calcium Excretion to Total Relative Amount of Creatinine Over 24 Hours by Day -1</title>
          <description>Total amount of urinary calcium excretion to total relative amount of creatinine over 24 hours by Day -1 was reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mmol/mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.806" spread="0.2284"/>
                    <measurement group_id="O2" value="0.836" spread="0.3020"/>
                    <measurement group_id="O3" value="0.727" spread="0.2859"/>
                    <measurement group_id="O4" value="0.874" spread="0.2670"/>
                    <measurement group_id="O5" value="0.855" spread="0.2858"/>
                    <measurement group_id="O6" value="0.807" spread="0.2764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Urinary Calcium Excretion to Total Relative Amount of Creatinine Over 24 Hours by Day 1/ Day 2</title>
        <description>Total amount of urinary calcium excretion to total relative amount of creatinine over 24 hours by Day 1/ Day 2 was reported.</description>
        <time_frame>Day 1- QD: Pre-dose up to 24 hours post dose, Day 2- BID: Pre-dose up to 24 hours post dose</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Urinary Calcium Excretion to Total Relative Amount of Creatinine Over 24 Hours by Day 1/ Day 2</title>
          <description>Total amount of urinary calcium excretion to total relative amount of creatinine over 24 hours by Day 1/ Day 2 was reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>millimoles Per millimoles (mmol/mmol)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.401" spread="0.1665"/>
                    <measurement group_id="O2" value="0.394" spread="0.1278"/>
                    <measurement group_id="O3" value="0.475" spread="0.1725"/>
                    <measurement group_id="O4" value="0.678" spread="0.2123"/>
                    <measurement group_id="O5" value="0.673" spread="0.2377"/>
                    <measurement group_id="O6" value="0.691" spread="0.2364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Urinary Excretion of Calcium Over 24 Hours by Day -1</title>
        <description>Total urinary excretion of calcium over 24 Hours by Day -1 was reported.</description>
        <time_frame>Day -1</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Urinary Excretion of Calcium Over 24 Hours by Day -1</title>
          <description>Total urinary excretion of calcium over 24 Hours by Day -1 was reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.348" spread="3.9559"/>
                    <measurement group_id="O2" value="10.239" spread="3.7130"/>
                    <measurement group_id="O3" value="8.880" spread="3.7407"/>
                    <measurement group_id="O4" value="10.831" spread="2.8306"/>
                    <measurement group_id="O5" value="10.735" spread="2.9224"/>
                    <measurement group_id="O6" value="9.717" spread="2.9354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Urinary Excretion of Calcium Over 24 Hours by Day 1/ Day 2</title>
        <description>Total urinary excretion of calcium over 24 hours by Day1/Day 2 was reported.</description>
        <time_frame>Day 1- QD: Pre-dose up to 24 hours post dose, Day 2- BID: Pre-dose up to 24 hours post dose</time_frame>
        <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Urinary Excretion of Calcium Over 24 Hours by Day 1/ Day 2</title>
          <description>Total urinary excretion of calcium over 24 hours by Day1/Day 2 was reported.</description>
          <population>PD analysis set. Here the number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>mmol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.904" spread="1.9684"/>
                    <measurement group_id="O2" value="5.137" spread="1.9800"/>
                    <measurement group_id="O3" value="6.037" spread="2.5353"/>
                    <measurement group_id="O4" value="7.440" spread="2.5379"/>
                    <measurement group_id="O5" value="8.813" spread="2.8213"/>
                    <measurement group_id="O6" value="7.928" spread="2.3159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAE's)</title>
        <description>An AE that occured during the study was considered a TEAE if it had a start date/time on or after the first dose of investigational product or if it had a start date before the date of the first dose of investigational product, but increased in severity on or after the date/time of the first dose of investigational product. Number of participants with TEAE's were reported.</description>
        <time_frame>From signing of informed consent up to follow up (up to Day 182)</time_frame>
        <population>Safety analysis set included enrolled participants who received at least 1 dose of rhPTH(1 84).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: Treatment A</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
          </group>
          <group group_id="O2">
            <title>Cohort II: Treatment C</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
          </group>
          <group group_id="O3">
            <title>Cohort I+II: Treatment B</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Cohort III: Treatment D</title>
            <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
          </group>
          <group group_id="O5">
            <title>Cohort IV: Treatment F</title>
            <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
          </group>
          <group group_id="O6">
            <title>Cohort III + IV: Treatment E</title>
            <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAE's)</title>
          <description>An AE that occured during the study was considered a TEAE if it had a start date/time on or after the first dose of investigational product or if it had a start date before the date of the first dose of investigational product, but increased in severity on or after the date/time of the first dose of investigational product. Number of participants with TEAE's were reported.</description>
          <population>Safety analysis set included enrolled participants who received at least 1 dose of rhPTH(1 84).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of informed consent up to follow up (up to Day 182)</time_frame>
      <desc>One participant during the washout out period following the 100 mcg QD dosing treatment period with calcium supplement in cohort III withdrew from the study and considered only in combined arm (Cohort III + IV).</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort I: Treatment A</title>
          <description>Participants received 25 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in cohort I.</description>
        </group>
        <group group_id="E2">
          <title>Cohort II: Treatment C</title>
          <description>Participants received 50 mcg rhPTH(1-84) BID with no calcium in the morning on Day 1 of respective treatment period in Cohort II.</description>
        </group>
        <group group_id="E3">
          <title>Cohort I+II: Treatment B</title>
          <description>Participants received 100 mcg rhPTH(1-84) QD with no calcium in both cohort I and II in the morning on Day 1 of respective treatment period.</description>
        </group>
        <group group_id="E4">
          <title>Cohort III: Treatment D</title>
          <description>Participants received 25 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort III.</description>
        </group>
        <group group_id="E5">
          <title>Cohort IV: Treatment F</title>
          <description>Participants received 50 mcg rhPTH(1-84) BID with calcium in the morning on Day 1 of respective treatment period in Cohort IV.</description>
        </group>
        <group group_id="E6">
          <title>Cohort III + IV: Treatment E</title>
          <description>Participants received 100 mcg rhPTH(1-84) QD with calcium in both cohort III and IV in the morning on Day 1 of respective treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Medical device site ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>1 866-842-5335</phone>
      <email>ClinicalTransparency@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

